207_Combined course Presentations
Is there a role for thoracic RT in ED-SCLC ? CREST trial
Overall Survival
Progression was less likely to occur in patients treated with thoracic RT ( PFS @ 6 months = 24% vs 7%, p = 0.001 )
OS @ 1 year: 33% vs 28% (p = 0.06) OS @ 2 years: 13% vs 3% (p = 0.004)
No differences in grade 3 or higher toxic effects
Many patients have relapse outside the thorax and the brain
Thoracic RT in addition to PCI should be considered for all ED- SCLC patients who respond to chemotherapy
Slotman B. et al. Lancet 2015;385
Made with FlippingBook